Novartis Ag

Thomas Knoepfel

Pascal Furet

Robin Alec Fairhurst

Robert Mah

Catherine Leblanc

Nicole Buschmann

Tao Jiang

Bo Han

Matthew J LaMarche

Yi Zhang

Guobao Zhang

Pierre-Yves Michellys

Can Wang

Songchun Jiang

Phillip B Alper

Jorge Garcia Fortanet

Lv Liao

Jing Xiong

Daniel Mutnick

Dale Porter

Xianglin Zhao

Markus Wartmann

Wei Pei

Diana Graus Porta

Jonathan Deane

Nafeeza Hafeez

Franck Mallet

Peter Syka

Phillip Alper

Julie Martz

The invention disclosed herein relates to 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridinyl compounds and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridinyl compounds of Formula (A), pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of autoimmune diseases. 

Compounds and compositions as inhibitors of endosomal toll-like receptors

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.

Formylated N-heterocyclic derivatives as FGFR4 inhibitors

A pharmaceutical combination comprising N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide, or a pharmaceutically acceptable salt thereof, and at least one active ingredient, as defined herein, or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, for simultaneous or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.

Pharmaceutical combinations

Growing community of inventors

Rheinfelden, Switzerland

Thomas Knoepfel